August 28, 2017 10:31 AM EDT
News Briefing

Bay­er, J&J eye block­buster sup­ple­men­tal OK for Xarel­to; Set­Point rais­es $30M for bio­elec­tron­ics

Shehla Shakoor

Managing Director

⇨ The an­ti-clot ther­a­py Xarel­to from Bay­er and J&J may have a much brighter fu­ture now that re­searchers have post­ed its ef­fect on pre­vent­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times